afternoon, our pipeline. and the positive focused BLA our program trial advance in results of and today's our stem X of first appreciate the cell transplant great Phase We addiction treatment of everyone. and joining TMA, us the in completion anticipated of you on our we're for sections to first Thank submission Jennifer, last quarter. clinical the toward you, compulsions narsoplimab for update. the from for next good a accomplished submitted half Omeros pre-clinical accelerating We deal We rolling and BLA year. announced associated and continued OMSXXX
start all of our OMIDRIA and I'll financials. with that, quarter In Today addition OMIDRIA record quarterly another revenues. of produced to
demand, driven $XX.X sales ASCs, an and those penetration first by number within The ordering all the the quarter increased delivered in other accounts increase growth came quarter. XX% in The hospitals, at substantial customers. increase net OMIDRIA across the both of VA, government of from record of million, and the third sales over accounts a channels,
The was $X.X $X.XX $X.XX non-cash or quarter per includes the or loss company's $XX.X which share, of million, per share. charges net for million,
$XX.X September XX, cash general for available XXXX, for of As quarter. we burn had representing million $X.X a operations, the million of
to of We Valley to with line accounts Bank. subject a enabled million line our balance, outstanding credit revolving credit of up also Silicon have XX% $XX receivable This us to facility of reserves. applicable borrow
the is with line under along expanding payer previous with strong J-code within increasing payer of will borrowed for have historically the fourth and expect coverage demand, drivers systems. physician to OMIDRIA growth, sales we QX be record credit. yet We various set key not Consistent sales of expected quarter. the revenues this another in are and OMIDRIA implementation
QX, value continue specifically the to to In pull-through We strong a to private further community demand surgeons of expanding generate focus a and hospitals. from strategy surgeons who purchasing our academic our and administrators. organizations, down, our from of the patients, groups, data, of group significant and expanding equity clinical see reinforcing top penetrate driving on cataract cataract OMIDRIA sales accounts, of broadening the execution by reflect continued base
prevents controlled, intraoperative clinical problems surgery, cataract major that substantial we call, the documenting earlier the OMIDIA continue In discussed Publications, showing in iris one syndrome quarterly clinical benefits an or the trials of OMIDRIA to randomized, grow of IFIS. number. floppy prospective, in
a OMIDRIA cataract assessing cystoid to epinephrine comparing for surgery. of sight-threatening edema, discussed steroids, well also and two the independent as postoperative macular need of CME, as the We studies incidents or complication
to shown X,XXX was of used, was OMIDRIA and the reduced approximately Across patients, three total steroids CME be incidence when of to were the unnecessary twelvefold.
Walter of of Keith by One publication beyond by iritis of other and Denise the authored Surgery. month expand University, Dr. Cataract the study Wake these was and study, Walter's and after breakthrough are to of Refractive benefits accepted CME last the Visco Results include Journal for Forest to published Dr. be Dr. conducted in two studies, expected pain.
author opioid and Analog important Dr. Refractive published on Ophthalmology, Surgery. the journal opioid use Donnenfeld, another President nearly the Scale, of investigator pain is clinical week, trial, in in half. fentanyl this OMIDRIA Visual last while also study or cutting in surgery In cataract Eric use. recent of the Just peer-reviewed Cataract Society effect XX%, by profound Past VAS was dangerous of the the well-controlled scores demonstrating OMIDRIA reduced Clinical reducing and study's American prospective, of The
The compelling and outcomes payers. OMIDRIA Medicare CMS of commercial, drive peer-reviewed to patient benefits B, that Med documenting publications of safety improve and set Advantage, expanding or government across and the helping Part sales other are scope
XX, continued ensure to XXXX, under working beneficiaries, efforts Regarding date. are expiration and non-opioid continue we exclusion. drug beyond with continued CMS we OMIDRIA's our to use separate avenue this payment sector Part that enjoy expiration qualify scheduled passthrough to Medicare B CMS' One payment September through until on for is from
established opioids its is prospective for that pain specifically are OPPS, medications. congressional Act, the financial peer-reviewed of the within that Through separately which administered CMS reducing demonstrate surgery, exclusion to Support non-opioid drug, system, and showing, a opioid separate evidence of ensure mandate, use. Congress incentives the use limits during claims of pay means rather absence non-opioid Support CMS when payment no there Act. utilization published than the data non-opioid CMS' outpatient for to benefit exclusion there using a drug's in payment enables the data, drug to The response to or
CMS a statistically peer-reviewed, trials. clinically results OMIDRIA, you the X, not products, within was and OMIDRIA, clinical of that and significant own congressional did Support prospective, for In other including final The CMS, Bipartisan aware, meaningful agency Congress's well-controlled, CMS' on despite provided the mandate to OMIDRIA, product data many directive, Act. the fit rule. November squarely rule, of yet from with likely the issued utilization and additional published XXXX grant exclusion As are OPPS single
leader Professor these expert University, conducted by CMS data Donnenfeld David data, provided international reducing use of In Perioperative and also Stanford fentanyl of disorder. received Clark pain was an the population Pain the and of in Dr. in review, Clark, importance of at use with surgery and and at-risk the OMIDRIA Anesthesiology his underscores Medicine not-yet-published review in opioid an management cataract patients.
exclusion its these With criteria CMS' OMIDRIA non-opioid clearly collective warrants payment. data, separate own meets for and
approved to medications as media, XX compounded during The by had incentives the presents when Last Week Oliver products of results were event, Lack This where can limited, patients Dallas, his host from XX-minute compounding John When to to of a recently opioids. surgeons about non-FDA saw FDA-approved cataract OMIDRIA in television mainstream cataract dangers blinded beyond to utilize to access concerns often products pharmacies. show product turn of tragic, we be is pharmacies used segment compounding on Tonight. surgery. examples and compounding a was brought pharmacies from other access
earlier, C-code. Medicaid for us said across see CMS, now VA. Many I groups, to and as of not commercial across expand separate in in OMIDRIA Advantage growth payer previously commercial, reimburse which payment and the retired the these permanent OMIDRIA Advantage, we would setting. all insurers, utilization well On J-code, the office enables Med continued received X, as under As a October Med drug's
continue OMIDRIA. secure advance can Medicare XXXX. ensuring legislative our Medicare well-published challenge payment to CMS, beyond Part and B, B or committed that as to for important the to will September we overcome as this beneficiaries before, we of continue respect separate ever efforts same to benefits Part and We've administrative and With OMIDRIA XX, remain to clinical access
of are administrative will As efforts our underway. believe and clinical part broad-based be efforts, additional these clinical legislative, We collective successful. studies
and this House This out in bipartisan groups' to of bill was CMS' be to access alternatives. unwillingness non-opioid number growing In to Representatives frustration fact, is week. bipartisan of legislation a appropriate expected provide with of introduced the borne reimbursement
provide Medicare trial, published directs and bill reduce to or in that like demonstrated in the clinical for use in hospital ASCs of a reimbursement in ability a to have replace or journal. treatments the through data outpatient clinical OMIDRIA setting The peer-reviewed opioids non-opioid separate CMS
Separate this we paying Congress years. appropriately be run Bill similar CMS introduction companion coming September and within planned will by the The expect would to to that OMIDRIA payment are reimbursed Senate weeks. XX, XXXX. for of beyond Members continue for attention issue, five is Bipartisan
development Let's our of transplant-associated approvals. regulatory turn on We'll start of now MASP-X, for our narsoplimab, from BLA the for our treatment pipeline. rolling with TMA. toward with cell update review which our the antibody targeting our FDA narsoplimab commercial to product agreed proposed schedule rapidly stem an moving In for is September,
been to toxicology, to review accelerate submitted. including FDA approval, pharmacology the non-clinical the BLA can review it agreed review FDA until because waiting begin month, the pharmacokinetics. to of we the them, sections for submitted rather line Rolling the entire BLA in the allows has sections schedule, and to as with they its Last receive time than
The clinical time. the anticipate scheduled priority for track year. further for for to BLA in be submission narsoplimab first Work followed FDA's remaining the half sections. of sections sections is the by review, which CMC on the to the of that next BLA review would a completion complete next, grant BLA of are overall the FDA We shorten will
is investigational outlining a we a for recently A received a EMA. product Europe, Pediatric or a or PIP, Pediatric the Marketing the Investigation or from prerequisite to Agency, the program In EMA's pediatric of Medicines Authorization of in Committee MAA. opinion the Application, population European positive Plan, acceptance development
our the narsoplimab EMA's years Successful after to the makes marketing TMA. the exclusivity. for for approval EMA in the stem allow to plan of now PIP will of PIP pediatric MAA until way also additional the paves submission up us cell narsoplimab completion defer of two completion acceptance of of for eligible of MAA.
submission our plan to marketing in filed. of been the the rolling approval a soon submit we have BLA BLA. MAA to the intend after not contents and both has We U.S. does EMA Although, for procedure, harmonize European
progressing commercial narsoplimab US launch and preparations are the in for also the of well. Our anticipated Europe
increase As stated stem common been this stem often internationally and leaders and of TMA, the the cell previously, of establish from we centers transplant to with complication to transplantation. awareness of for treatment diagnosis cell have top fatal top guidelines working
Recently, outcomes, and centers to will that guidelines a the TMA begin the Omeros current new anticipate patient appropriately for discuss We guidelines convened identify TMA and cell transplanters stem to to top treatment. patients establishing earlier. improve US of group enabling by treat help cell diagnostic paradigm stem
next known recognition stem opinion a substantial unmet the leaders, in activator of there with discussions TMA. of need in at significant We educational of our endothelial TMA Orlando. There, focus will Society a we increasing awareness to directed Hematology continue American campaign lectin upcoming on strong and and growing on will of and advisors is a our MASP have Based cause, which the damage, pathway. the presence other its meeting month X with is cell
can Last you the updated stem quarter, and effort cell for the data potential proposition. we confident continued treat strong to payers, In on narsoplimab TMA of and that physicians value narsoplimab. story cost patients them, payer them. interactions advance centers narsoplimab on and bring offer creation and to these that both derived we QX, with will I remain that to transplant our from this interactions and value the evaluate working Based centers value the a
right indicates about stem our about As top cell up in of the US US the centers, work transplant targeting XXX XX for for the with making of to centers of other concentration the allogeneic the centers, transplants expect our year. commercial top occur focused salesforce US preparations, begin approach within expertise XX% XX% these the that allows transplant. in of building number us bringing a This and within relatively on market and focus this small US indication next early we to narsoplimab our resources, allogeneic
similar countries. EU in dynamic commercial across Europe the Our is top indicate a that preparations there
Our physicians, is to launch for for right team centers, the payers our doing narsoplimab shareholders. a patients, successful and prepare things of
Overall, Phase We Phase at number North our Europe X for trial accelerate to X of nephropathy. and program and are continues also IgA America, across sites advancing an other narsoplimab international increasing our in enrollment catchments.
levels greater the in at this Either also of proteinuria X trial patients result a of XX-hour proteinuria In least addition accelerated daily, based than gram can on or is populations X general enrolling population grams. approval, with patients these alone. two reduction proteinuria of with of full to subset
years. in the peer-reviewed would singular drug eGFR full timeframe full To nephropathy is data, glomerulonephritis comprised the which publication. approval prepared the is narsoplimab expected can that patient alone. leadership X avoid from academic to published renal truncating committee, leaders as vasculitis-associated collect world the journal. program, on with A for proteinuria much IgA and the report and a nephritic, submitted obtain best our of of This has to IgA process by three detailing been only knowledge, narsoplimab required long IgA by clinical in by rapidly be in A distinction progressive manuscript clinical nephropathy the is to the nephropathy approval Omeros' research response as development IgA Phase treatment a detailing data for
In patients in responsive identification could administered as of the U.S. and This subcutaneous is subcutaneously or separate is trial dosing The Europe of syndrome narsoplimab aHUS. September, pharmacodynamics to diagnosis, biomarkers patients earlier being evaluating inhibition. which as evaluating across IgA with uremic trial we aid began a used nephropathy. and for well study and sites multiple most MASP-X includes our actively Phase the patients is pharmacokinetics of in Chronic atypical hemolytic enrolling in also enrolling. an disease, narsoplimab study the potential this and in X
with franchise, believe in complement our in antibody research alternative is the targeting MASP-X along that OMSXXX, turn We premier to our drug and target complement industry the let's pathway. of and MASP-X. community key activator another in others Now component the the
Potential range broad include OMSXXX disorders. indications of for a pathway alternative
Our initial on is Paroxysmal nocturnal or PNH. hemoglobinuria, focus
OMSXXX market in or We the over development advantages have on inhibitors pathway to PNH. currently other significant the alternative for expect
hemolysis, inhibit lower MASP-X a The inhibition inhibition frequency and convenient dosing. with potent include providing intravascular while self-administered of the profile, route extravascular advantages of ability more administration much hemolysis, favorable to more safety collective of of a
in Toxicology OMSXXX OMSXXX to are next less the of or is manufacturing twice dosed in the monthly, and first year. slated expected GMP to be enter subcutaneously half frequently. clinic is underway, studies
XXXX. orally in molecule progress we clinical inhibitors life strategy we complement OMSXXX, our franchise to management for as are and for developing second As well We're generation antibody, against a also Narsoplimab as of we both in whole. MASP-X, available our are longer-acting targeting our advancing continue the cycle entry small of both as which
of We also continue inhibitors developing molecule MASP-X. small
randomized treat phosphodiesterase was addictions our drug demonstrated in the to with once-daily profile good trial. consistent compulsions, and well-tolerated PK or dosing. reported we and study, X, X positive In to from Moving double-blind Phase PDEX results program September, our Its safety. our was
the with nicotine Phase largest the the use is for a million of people, addiction, especially development for and preventable cause need epidemic in focus toll further addiction. popularity of U.S., Our a disease are new The young of of half nearly people. of and our program. single emerging national death planning X Tobacco a represents treatments e-cigarettes, newly among we death nicotine nicotine dependence, underscoring
with with Let's that the update collaborators team an Research close pipeline discussion our for on were week, Canada Toronto of program. of Prix GPCR recognition Last strength importance is platform. underlying academic the our we a announced from our North awarded Galien along proprietary University and Omeros GPCR Award the award Omeros' Validating the innovation. is prestigious America's program, Prix most from GPCR in the and of discoveries in research of the field pharmaceutical XXXX Galien
platform GPCR of compounds. technology, and result we our GPCRs a XX corresponding As drug targets controlled
would discoveries demonstrating announced the of share cancer we I that, series quarterly axis GPRXXX we showing new indicated our soon a last In controls to a cancer relevance immunotherapy. in GPRXXX August. September, immunity. of in our On that call data
we inhibition a response. by antagonist Omeros' cancer number of both of as inhibitors While immunotherapy enhancement cytokine anti-cancer now GPRXXX of combined adenosine GPRXXX T-cells. both solo pathway, immunity, that an inhibition of that tumor GPRXXX are the another turns development combined a potential efforts inhibition maximal in focus of key have the by metabolic inhibitors, pathway enhances It out though in with that synergistically of shown receptor has results regulates combined pathway Adenosine adenosine production T-cell significant agent, novel one companies. the pathways,
to and making which tumor work, data checkpoint tumor inhibitors kill significantly tumor. only balance, including is of today. checkpoint immune efficacy best, able this drugs The to the importance inhibitors in effective. anti-cancer other of about XX% the inhibitors a own major tumor like that this the on of KEYTRUDA OPDIVO, could is or agents, the body's anti-cancer response shift patients This in well microenvironment, immunosuppression more show at where The suppress the lies limitation the GPRXXX
will new and American model for presented the the Our tumor work later Research. Boston, human at conference data, Association as animal exciting month this of in well as cells, with be Cancer
at are similar and positive, scientific community we both and the present to we as strongly response in been bringing the clinic possible. our a to month, from Geneva. scheduled Next conference has to GPRXXX to The as look forward industry inhibitors GPRXXX program soon
for that, quarter turn an third our call overview financial With over the to results. Mike I'll of
